acetylated peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-02. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Will Self, novelist (Jewish mother); son of Peter Self, and grandson of Sir Albert Henry Self Charles Gabriel Seligman FRS FRAI (né Seligmann; 24 December 1873 – 19 September 1940) was author, scholar, academic, physician and ethnologist; main ethnographic work described culture of Vedda people of Sri Lanka and Shilluk people of Sudan; was professor at London School of Economics; influential as the teacher of Bronisław Malinowski, E. E. Evans-Pritchard, and Meyer Fortes; was proponent of the Hamitic hypothesis, according to which some civilisations of Africa were thought to have been founded by Caucasoid Hamitic peoples. His work in the 1920s and 1930s is now seen as "white supremacist". Nicholas Serota (born 27 April 1946), author, art historian and curator; served as Director of the Tate from 1988 to 2017; currently Chair of Arts Council England; was previously Director of The Museum of Modern Art, Oxford, and Director of the Whitechapel Gallery, before becoming Director of the Tate; was also Chairman of the Turner Prize jury. Malcolm Shaw (academic) KC (born 1947), British legal academic, author, editor and lawyer; studied at University of Liverpool (LLB), Hebrew University of Jerusalem (LLM) and Keele University (PhD); was the Sir Robert Jennings Professor of International Law at the University of Leicester and taught international law, human rights and equity and trusts; appointed as Senior Fellow at Lauterpacht Centre for International Law at University of Cambridge; Trustee of the British Institute of International and Comparative Law.
== Function == The function galectin-7 has recently been found to be a critical role in is with skin tissue linking to skin cancers because of its involvement with apoptosis from the LGALS7 gene that the protein is produced from, though it still is involved with the oral cavity, esophagus, epidermis, and cornea, with skin cancer being the most notable one. During skin repair, cell migration is the process by which cells close a wound which includes the epidermal keratinocytes migration which re-established the skin barrier, re-epithelialization. The protein's involvement, if deficient, can result in a defect of cell migration leading to less proficient skin repair as well. Re-epithelialization, skin repair, the regulation of cell migration, and cell adhesion is also expressed within skin tumors and still needs to be better researched as its abnormal expression in carcinomas, cancer progression, and metastasis is still not understood in terms of its function. While the protein's function in the nucleus is still unknown, the diverse studies for the cellular function in mitochondria and cytosol link pathways to regulation of keratinocyte and differentiation while also having a mutation bind to a hot spot called the galectin-7 promoter. Galectin-7 regulates cell growth, cell differentiation, and apoptosis in epithelial maintenance roles but there are still many unknowns when it comes to this protein in its role of cellular processes.
== History == References to dedifferentiation can be found as far back as 1915, where Charles Manning Child described dedifferentiation as a “return or approach to the embryonic or undifferentiated condition”. While Manning's research was about plants, it helped establish the foundation for our modern-day understanding of dedifferentiation and cell plasticity. Just as plant cells respond to injury by undergoing callus formation via dedifferentiation, some animal models dedifferentiate their cells to form blastema, which are analogous to plant calluses, after limb amputation. In the 1940s C. H. Waddington created the “Epigenetic Landscape”, a diagrammatic representation of cell fate from less differentiated to more differentiated cell types. Here, the concept of a marble moving downhill through various paths is used to represent cell decision-making and cell potency, thus visualizing how cells can take different paths of differentiation to reach a final state. Dedifferentiation would be represented by the marble moving uphill through the pathways it has already taken until it settles somewhere above the most downhill location. In our modern-day understanding of dedifferentiation, some controversies remain when defining the boundaries of its definition. Some claim that dedifferentiation is strictly limited to the same cell lineage from which it is derived. However, others say that it can be used to describe a general increase in cell potency.
Sources: en.wikipedia.org
=== Preclinical === AB-300 (AB300) – non-hallucinogenic serotonin 5-HT2A and 5-HT2C receptor agonist AB-5006 (AX-5006) – Escherichia coli csgA protein aggregation inhibitor and gastrointestinal microbiome modulator [96] AEX-23 – orexin OX1 receptor agonist and α-synuclein aggregate/modulator [97] Afamelanotide ([Nle4,DPhe7]-α-MSH; CUV-1647; EPT-1647; Melanotan I; Melanotan; MT-I; Prenumbra; Scenesse) – melanocortin receptor agonist [98] Alpha-synuclein aggregation inhibitor (ACI-5755; morphomer α-synuclein) – α-synuclein inhibitor [99] BEBT-758 – RNA interference and α-synuclein expression inhibitor [100] Bevemipretide (SBT-272) – cardiolipin ligand and stabilizer [101] BSC-3301 – receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor [102] BXQ-350 (SapC; SapC-DOPS; sphingolipid activator protein C) – sphingomyelin phosphodiesterase stimulant and sphingosine 1-phosphate stimulant [103] Cannabidiol (CBD) – cannabinoid receptor modulator and other actions [104] Carbon monoxide (CO; HBI-002) – heme oxygenase 1 modulator [105] CB-401 – amyloid β-protein modulator [106] CBT-102 – undefined mechanism of action [107] CJRB-301 (MRx-0005) – bacteria replacement and microbiome modulator [108] CJRB-302 (MRx-0029) – bacteria replacement and microbiome modulator [109] CK-0803 – regulatory T-lymphocyte replacement [110] CU-13001 – 15-lipoxygenase (15-LOX/ALOX15) inhibitor [111] EHP-102 (VCE-003.2) – cannabinoid CB2 receptor agonist and peroxisome proliferator-activated receptor alpha (PPARα) modulator (cannabigerol (CBG) derivative) [112] Estianeptine ((S)-tianeptine; TNX-4300) – peroxisome proliferator-activated receptor PPARβ/δ and PPARγ agonist [113] FHL-401 – toll-like receptor 2 antagonist [114] FHL-701 – interleukin-12 (IL-12) subunit p40 inhibitor [115] FKK-01PD (FKK-01PD; TGHW-01AP; apomorphine prodrug) – non-selective dopamine receptor agonist and other actions [116] HT-4403 – leucine-rich repeat kinase 2 (LRRK2) inhibitor [117] IC-100 (ICCN-100) – various actions [118] KFRX-05 (BK-40195) – leucine-rich repeat kinase 2 (LRRK2) inhibitor and protein tyrosine kinase inhibitor [119] KP-405 – undefined mechanism of action [120] LB-P4 – bacteria replacement and microbiome modulator [121] Mbiotix – bacteria replacement and microbiome modulator [122] ML-021 – muscarinic acetylcholine M4 receptor antagonist [123] MP-201 – 2,4-dinitrophenol (DNP) prodrug and various actions [124] NB-003 – gene transference and parkin protein replacement [125] NB-129 – undefined mechanism of action [126] NLY-02 – glial cell inhibitor [127] NLY-03 – undefined mechanism of action [128] NNI-362 – 70 kDa ribosomal protein S6 kinase modulator [129] NRG-5051 – mitochondrial permeability transition pore inhibitor [130] PMN-442 – monoclonal antibody against α-synuclein [131] PP-003 – α-synuclein degrader [132] Research programme: 3100 programme - DigmBio/Daegu Catholic University – G protein-coupled receptor (GPCR) modulators [133] Research programme: enzyme targeted therapeutics - Nitrase Therapeutics – enzyme modulators and α-synuclein inhibitors [134] Research programme: neurodegenerative disease therapeutics - Caraway Therapeutics – autophagy stimulants and MCOLN1 stimulants [135] RGL-193 – undefined mechanism of action [136] ST-502 – gene therapy and α-synuclein genetic transcription inhibitor [137] Tomaralimab (NM-101; NM-102; NM-103; OPN-305) – monoclonal antibody against toll-like receptor 2 [138] Zervimesine (CT-1812; Elayta) – sigma σ2 receptor antagonist [139]
KSCN + 2 H2SO4 + H2O → KHSO4 + NH4HSO4 + COS The resulting gas contains significant amounts of byproducts and requires purification. Hydrolysis of isothiocyanates in hydrochloric acid solution also affords COS.
Mother Eddy deserves a place in the Trinity as much as any member of it. She has organized and made available a healing principle that for two thousand years has never been employed, except as the merest guesswork. She is the benefactor of the age." — Mark Twain, A Biography, by Albert B. Paine, Vol. III, p. 1271."
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.